• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于多环马来酰亚胺的支架作为探索大麻素系统机遇的新型优势结构。

Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.

作者信息

Bisi Alessandra, Mokhtar Mahmoud Alì, Allará Marco, Naldi Marina, Belluti Federica, Gobbi Silvia, Ligresti Alessia, Rampa Angela

机构信息

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.

Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy.

出版信息

ACS Med Chem Lett. 2019 Feb 26;10(4):596-600. doi: 10.1021/acsmedchemlett.8b00594. eCollection 2019 Apr 11.

DOI:10.1021/acsmedchemlett.8b00594
PMID:30996802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6466824/
Abstract

The discovery of the relevant role played by a dysregulation of the endogenous cannabinoid system in several pathological conditions has prompted an extensive research in this field. In this Letter, a series of cannabinoid receptor ligands bearing a previously unexplored polycyclic scaffold was designed and synthesized, in order to evaluate the potential of a new easily affordable privileged structure. The new compounds showed an appreciable affinity and a significant selectivity for the CB2 receptor and are endowed with an intriguing noncompetitive antagonist behavior. Due to the ability of the polycyclic structure to be easily modified in different ways, these compounds could represent convenient chemical tools to be exploited in order to better understand the endocannabinoid system impact on physiopathological conditions.

摘要

内源性大麻素系统失调在多种病理状况中所起的相关作用的发现,促使了该领域的广泛研究。在本信函中,设计并合成了一系列带有先前未探索过的多环骨架的大麻素受体配体,以评估一种新的易于获得的优势结构的潜力。新化合物对CB2受体表现出可观的亲和力和显著的选择性,并具有有趣的非竞争性拮抗行为。由于多环结构能够以不同方式轻松修饰,这些化合物可能代表方便的化学工具,可用于更好地理解内源性大麻素系统对生理病理状况的影响。

相似文献

1
Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.基于多环马来酰亚胺的支架作为探索大麻素系统机遇的新型优势结构。
ACS Med Chem Lett. 2019 Feb 26;10(4):596-600. doi: 10.1021/acsmedchemlett.8b00594. eCollection 2019 Apr 11.
2
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.基于聚环酰亚胺的衍生物作为治疗阿尔茨海默病的神经元钙通道和 GSK-3β的双重调节剂。
Eur J Med Chem. 2019 Feb 1;163:394-402. doi: 10.1016/j.ejmech.2018.12.003. Epub 2018 Dec 3.
3
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.基于三维定量构效关系分析的大麻素受体 2 高选择性配体的合理设计。
Eur J Med Chem. 2011 Feb;46(2):547-55. doi: 10.1016/j.ejmech.2010.11.034. Epub 2010 Nov 27.
4
Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.1,3,5-三嗪作为大麻素CB2受体激动剂的合成、体外及体内评价
Eur J Pharm Sci. 2015 Jan 25;67:85-96. doi: 10.1016/j.ejps.2014.11.003. Epub 2014 Nov 14.
5
Targeting the Bacterial Membrane with a New Polycyclic Privileged Structure: A Powerful Tool To Face Infections.利用新型多环优势结构靶向细菌膜:应对感染的有力工具
ACS Infect Dis. 2019 Sep 13;5(9):1524-1534. doi: 10.1021/acsinfecdis.9b00072. Epub 2019 Jul 12.
6
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.新型 CB2 选择性大麻素受体配体的合理设计、合成及抗增殖活性研究:1,8-萘啶-2(1H)-酮骨架的探索。
Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.
7
Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.大麻素CB1和CB2受体吲哚配体亲和力和选择性的比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)模型的开发。
Eur J Med Chem. 2009 Jun;44(6):2482-96. doi: 10.1016/j.ejmech.2009.01.026. Epub 2009 Feb 3.
8
Crystal Structure of the Human Cannabinoid Receptor CB2.人源大麻素受体 CB2 的晶体结构
Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.
9
Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.高选择性、胺衍生的大麻素受体 2 探针。
Chemistry. 2020 Jan 27;26(6):1380-1387. doi: 10.1002/chem.201904584. Epub 2020 Jan 21.
10
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.围绕4-氧代-1,4-二氢喹啉-3-甲酰胺类进行的药物调制,一类强效CB2选择性大麻素受体配体:对受体亲和力和功能的影响。
J Med Chem. 2007 Nov 1;50(22):5471-84. doi: 10.1021/jm070387h. Epub 2007 Oct 4.

引用本文的文献

1
Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL).乙醇蒽及相关化合物的合成与生化评价:对慢性淋巴细胞白血病(CLL)的抗增殖和促凋亡作用
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1034. doi: 10.3390/ph17081034.
2
Self-Assembly Nanoparticles of Natural Bioactive Abietane Diterpenes.天然生物活性枞烷二萜的自组装纳米粒子。
Int J Mol Sci. 2021 Sep 22;22(19):10210. doi: 10.3390/ijms221910210.
3
Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt's Lymphoma.靶向伯基特淋巴瘤的新型乙蒽及其相关化合物的设计、合成与生化评价
Pharmaceuticals (Basel). 2020 Jan 17;13(1):16. doi: 10.3390/ph13010016.

本文引用的文献

1
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.基于聚环酰亚胺的衍生物作为治疗阿尔茨海默病的神经元钙通道和 GSK-3β的双重调节剂。
Eur J Med Chem. 2019 Feb 1;163:394-402. doi: 10.1016/j.ejmech.2018.12.003. Epub 2018 Dec 3.
2
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.CB2 大麻素受体作为对抗阿尔茨海默病的潜在靶点。
Front Neurosci. 2016 May 31;10:243. doi: 10.3389/fnins.2016.00243. eCollection 2016.
3
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.大麻素受体2(CB2)激动剂和拮抗剂:专利综述
Expert Opin Ther Pat. 2016 Jul;26(7):843-56. doi: 10.1080/13543776.2016.1193157. Epub 2016 Jun 7.
4
Cannabinoid pharmacology in cancer research: A new hope for cancer patients?大麻素药理学在癌症研究中的应用:癌症患者的新希望?
Eur J Pharmacol. 2016 Mar 15;775:1-14. doi: 10.1016/j.ejphar.2016.02.010. Epub 2016 Feb 5.
5
Ligands for cannabinoid receptors, promising anticancer agents.大麻素受体的配体,有望成为抗癌药物。
Life Sci. 2016 Feb 1;146:124-30. doi: 10.1016/j.lfs.2015.12.053. Epub 2016 Jan 5.
6
Endocannabinoid signaling at the periphery: 50 years after THC.外周内源性大麻素信号传导:四氢大麻酚发现50年后
Trends Pharmacol Sci. 2015 May;36(5):277-96. doi: 10.1016/j.tips.2015.02.008. Epub 2015 Mar 18.
7
Design, synthesis and biological profile of new inhibitors of multidrug resistance associated proteins carrying a polycyclic scaffold.设计、合成及多药耐药相关蛋白新型抑制剂的生物特征研究,该抑制剂含有多环支架。
Eur J Med Chem. 2015 Mar 6;92:471-80. doi: 10.1016/j.ejmech.2015.01.004. Epub 2015 Jan 5.
8
Endocannabinoid signalling and the deteriorating brain.内源性大麻素信号与恶化的大脑。
Nat Rev Neurosci. 2015 Jan;16(1):30-42. doi: 10.1038/nrn3876.
9
The endocannabinoid signaling system in cancer.癌症中的内源性大麻素信号系统。
Trends Pharmacol Sci. 2013 May;34(5):273-82. doi: 10.1016/j.tips.2013.03.003. Epub 2013 Apr 17.
10
Cannabinoids: a new hope for breast cancer therapy?大麻素:乳腺癌治疗的新希望?
Cancer Treat Rev. 2012 Nov;38(7):911-8. doi: 10.1016/j.ctrv.2012.06.005. Epub 2012 Jul 7.